Mamuna Naz, Uzma Saleem, Bashir Ahmad
Faculty of Pharmacy, The University of Lahore, Lahore-Pakistan.Assistant Professor, Faculty of Pharmaceutical Sciences, G. C. University, Faisalabad-Pakistan. Director / Professor, Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore-Pakistan.
Keywords: In vivo antioxidant activity, hypolipidemic, hepato-renal curative

Background: Plants are rich source of antioxidants. They can ameliorate the oxidative stress induced complications. Cisplatin is a cytotoxic drug which produced unwanted effects in the patients due to generation of free radicals inside the body. Phyllanthus emblicuspossessed in vitro antioxidant activity. Objective: The current study was aimed to explore in vivo antioxidant potential of Phyllanthus emblicus against the oxidative stress induced by cisplatin in mice. Method: oxidative stress was induced in micewith acute toxic dose (10 mg/kg) of cisplatin given i.p. Animals were divided into five groups (n = 5). Group I: negative control, group II: positive control group III and IV were given methanol extract ofPhyllanthus emblicus (250- & 500 mg/kg; orally respectively) and group V was standard group receiving orally vitamin C & E (200 mg/kg each) for 20 days. On 21st day, animals were sacrificed and oxidative stress biomarkers were quantified. Result: Phyllanthus emblicusextract showed vigorous in vivo antioxidant effect at 500mg/kg by increasing the SOD, CAT, and GSH (antioxidant enzymes) levels in heart, liver, kidney and brain homogentaes and MDA level decreased. Plant also displayed a cure against oxidative stress induced changes in renal, liver and lipid profile parameters. Conclusion: Phyllanthus emblicusraised antioxidant enzyme levels in mice. It manifested hypolipidemic, hepato-renal curative effects. Its adjuvant use with standard therapies may help to resolve unwanted effects.

Article Information

Identifiers and Pagination:
First Page:1
Last Page:6
Publisher Id:19204159.8:1.2016
Article History:
Received:October 06,2015
Accepted:November 13,2015
Collection year:2015
First Published:January 1, 2016

© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license. You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
Editor in Chief
Prof. Dr. Cornelia M. Keck (Philipps-Universität Marburg)
Marburg, Germany


Welcome to the research group of Prof. Dr. Cornelia M. Keck in Marburg. Cornelia M. Keck is a pharmacist and obtained her PhD in 2006 from the Freie Universität (FU) in Berlin. In 2009 she was appointed as Adjunct Professor for Pharmaceutical and Nutritional Nanotechnology at the University Putra Malaysia (UPM) and in 2011 she obtained her Venia legendi (Habilitation) at the Freie Universität Berlin and was appointed as a Professor for Pharmacology and Pharmaceutics at the University of Applied Sciences Kaiserslautern. Since 2016 she is Professor of Pharmaceutics and Biopharmaceutics at the Philipps-Universität Marburg. Her field of research is the development and characterization of innovative nanocarriers for improved delivery of poorly soluble actives for healthcare and cosmetics. Prof. Keck is executive board member of the German Association of Nanotechnology (Deutscher Verband Nanotechnologie), Vize-chairman of the unit „Dermocosmetics“ at the German Society of Dermopharmacy, active member in many pharmaceutical societies and member of the BfR Committee for Cosmetics at the Federal Institute for Risk Assessment (BfR).

Journal Highlights
Abbreviation: J App Pharm
Frequency: Annual 
Current Volume: 9 (2017)
Next scheduled volume: December, 2018 (Volume 10)
Back volumes: 1-9
Starting year: 2009
Nature: Online 
Submission: Online  
Language: English

Subject & Scope
  • Pharmaceutics
  • Physical Pharmacy 
  • Dosage Forms Science 
  • Pharmaceutical Microbiology & Immunology 
  • Industrial Pharmacy 
  • Bio-Pharmaceutics 
  • Pharmaceutical Chemistry 
  • Pharmaceutical Instrumentation 
  • Medicinal Chemistry 
  • Pharmacognosy 
  • Physiology &Histology 
  • Anatomy & Pathology 
  • Pharmacology & Therapeutics 
  • Pharmacy Practice 
  • Pharmaceutical Mathematics   
  • Biostatistics 
  • Dispensing 
  • Community Social & Administrative Pharmacy 
  • Hospital Pharmacy 
  • Clinical Pharmacy 
  • Pharmaceutical Quality Management 
  • Forensic Pharmacy 
  • Pharmaceutical Technology 
  • Pharmaceutical Management & Marketing

Consortium Publisher is an online publisher that enjoys global presence with International Journals

Follow Us

©2009 - 2019 Consortium Publisher Canada

Contact Info

6252 Lisgar Dr Mississauga Ontario L5N7V2 Canada
+1 (647) 526-0885